Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool May 16, 2005 Ellen Dowling	Merck Minds Its Manners The drug giant's handbook for its salespeople has Congress offended. Whether the committee thinks its salespeople are charismatic or just plain con artists, Merck's actions will eventually speak louder than its words for patient investors.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
The Motley Fool May 27, 2005 Stephen D. Simpson	Once More With Merck Merck has had a busy spring, but are investors any better off?
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
The Motley Fool April 21, 2005 Stephen D. Simpson	Merck Looks for Soft Landing Despite a tough year, the business isn't falling apart, and the pipeline has some near-term gems. This should give investors reason to expect that better things could be on the way.
The Motley Fool April 20, 2006 Stephen D. Simpson	Wait for More Bad News on Merck Vioxx lawsuits will be an ever-present headline risk for a while, but I still believe it's highly unlikely that they'll do lasting damage to the business. That said, the nearly 30% rise in this stock since late '05 has taken a lot of the easy money off the table.
The Motley Fool May 12, 2010 Brian Orelli	Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong.
The Motley Fool March 2, 2010 Brian Orelli	Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool November 30, 2004 Rich Smith	Merck Execs Circle the Wagons Shareholder anger is elicited by a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves.
The Motley Fool July 21, 2005 Stephen D. Simpson	Merck Is No Quack Weighing the pros and cons, it appears that Merck's stock is trading pretty much where it should be. What does make the story a bit more interesting is that robust dividend, which is currently yielding almost 4.8%.
The Motley Fool May 5, 2010 Brian Orelli	Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
Chemistry World October 4, 2013 Andy Extance	Amid huge cuts, Merck vows research focus US-based drug giant Merck & Co will cut 8,500 more jobs as it seeks to cut costs by $2.5 billion
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
The Motley Fool June 3, 2005 Brian Gorman	Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool January 31, 2006 Stephen D. Simpson	Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here.
BusinessWeek September 20, 2004 Amy Barrett	Merck: Who Will Revive The Giant? Earnings and new-drug disappointments have investors worried about succession.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool November 29, 2010 Brian Orelli	There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.
The Motley Fool October 28, 2005 Stephen D. Simpson	Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
The Motley Fool October 24, 2005 Stephen D. Simpson	Merck Needs to Take Its Medicine It will be a long, long time before business at the pharmaceutical returns to business as usual. Turnarounds can pay off for patient investors.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool June 30, 2008 Brian Orelli	A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
The Motley Fool April 7, 2005 Brian Gorman	Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments.
The Motley Fool November 27, 2007 Brian Orelli	Second Chance for Merck's MEVACOR Merck licenses the rights to an over-the-counter version of its cholesterol-lowering drug MEVACOR to GlaxoSmithKline, but the deal is far from done. Investors, take note.
The Motley Fool April 21, 2009 Brian Orelli	Schering and Merck: A Match Made in Purgatory Until Merck can show that it's capable of growing sales again, investors should be leery of stepping in, even with the dividend yield pushing 6%.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool July 18, 2008 Brian Orelli	Foolish Forecast: How Quickly Can Merck Turn It Around? Views you can use to get clues on the news.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool May 4, 2006 Stephen D. Simpson	AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch.
Fast Company March 2004 Jennifer Reingold	CEO See-Ya! Raymond Gilmartin, CEO of Merck & Co. gets the ax.
The Motley Fool February 3, 2011 Brian Orelli	Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window.
The Motley Fool January 14, 2011 Brian Orelli	Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing.
The Motley Fool November 3, 2009 Brian Orelli	A Little Distracted, Are You, Merck? The FDA rejects its latest application.